No description available.

No description available.

Current dissolution apparatuses require several hundred milligrams of sample per trial, measure dissolution rate indirectly via concentration sampling, and cannot maintain sink conditions throughout the duration of a test. This work describes a novel dissolution testing methodology developed using a commercial quartz crystal microbalance (QCM) system to measure dissolution rates of drugs while overcoming the limitations of current dissolution methods. The apparatus was characterized for a sample drug system of benzoic acid dissolved using a dissolution medium of deionized water at flow rates of 1000, 100, 50, and 10 &mgr;L/min. Using an analysis method that combines the responses of resonance frequency and resistance of the quartz crystal during dissolution, the dissolution rate of benzoic acid was found to be 4.029 ± 0.743, 2.026 ± 0.913, 1.565 ± 0.349, and 1.060 ± 0.103 % mass/s, for each flow rate, respectively. The QCM dissolution apparatus method can be used to measure drug dissolution directly by quantifying mass loss (rather than indirectly via concentration changes as with current methods), reduce sample sizes compared with current methods by three orders of magnitude onto the microgram scale, and maintain sink conditions throughout the duration of the test.

<p>The general aim of the present project was to increase the understanding of the in vivo dissolution of poorly soluble drugs and thereby improve possibility to predict in vivo solubility from substance properties. Increased understanding of the in vivo limitations of drug solubility could potentially also generate ideas for improved formulation principles for poorly soluble compounds and more relevant in vitro dissolution test methods used in formulation development.</p><p>The dynamic gastrointestinal secretory and enzymatic responses to a liquid meal were studied in human intestinal fluid (HIF) by in vivo perfusion of a nutritional drink. The main diversity found compared to simulated intestinal fluids was the presence of dietary lipids in fed human intestinal fluid. This difference was showed to be of importance in the solubility of low soluble drugs, since this parameter was underestimated in the simulated fluid. Thus suggesting that simulated intestinal fluids should be prepared with the addition of dietary lipids for better in vitro in vivo predictions. </p><p>Solubility and dissolution determinations in fasted and fed HIF showed that the solubility was higher in fed state fluid, probably owing to the higher concentration of lipids in this media. The higher solubility was correlated to both the lipophilicity and aqueous solubility of the drug. The dissolution rate also increased, but not to the same extent as the solubility. These findings need to be considered in the design of in vitro models and in the prediction of food effects on oral bioavailability of poorly soluble drugs.</p><p>In addition, an in vivo porcine perfusion study was performed to investigate importance of different mechanisms in food-drug interactions. The results showed that solubilisation might be a more important factor than P-gp inhibition for food-related effects on the intestinal absorption kinetics of Class II drugs. </p>

The general aim of the present project was to increase the understanding of the in vivo dissolution of poorly soluble drugs and thereby improve possibility to predict in vivo solubility from substance properties. Increased understanding of the in vivo limitations of drug solubility could potentially also generate ideas for improved formulation principles for poorly soluble compounds and more relevant in vitro dissolution test methods used in formulation development. The dynamic gastrointestinal secretory and enzymatic responses to a liquid meal were studied in human intestinal fluid (HIF) by in vivo perfusion of a nutritional drink. The main diversity found compared to simulated intestinal fluids was the presence of dietary lipids in fed human intestinal fluid. This difference was showed to be of importance in the solubility of low soluble drugs, since this parameter was underestimated in the simulated fluid. Thus suggesting that simulated intestinal fluids should be prepared with the addition of dietary lipids for better in vitro in vivo predictions. Solubility and dissolution determinations in fasted and fed HIF showed that the solubility was higher in fed state fluid, probably owing to the higher concentration of lipids in this media. The higher solubility was correlated to both the lipophilicity and aqueous solubility of the drug. The dissolution rate also increased, but not to the same extent as the solubility. These findings need to be considered in the design of in vitro models and in the prediction of food effects on oral bioavailability of poorly soluble drugs. In addition, an in vivo porcine perfusion study was performed to investigate importance of different mechanisms in food-drug interactions. The results showed that solubilisation might be a more important factor than P-gp inhibition for food-related effects on the intestinal absorption kinetics of Class II drugs.

<p>Supersaturating drug delivery systems are an attractive solubility enabling formulation strategy for poorly soluble drugs due to their potential to significantly enhance solubility and hence, bioavailability. Compendial dissolution testing is commonly used a surrogate for assessing the bioavailability of enabling formulations. However, it increasingly fails to accurately predict <i>in vivo</i> performance due its closed-compartment characteristics and the lack of absorptive sink conditions. <i>In vivo</i>, drug is continually removed due to absorption across the gastrointestinal membrane, which impacts the luminal concentration profile, which in turn affects the dissolution kinetics of any undissolved material, as well as crystallization kinetics from supersaturated solutions. Thus, it is critical to develop an improved methodology that better mimics <i>in vivo</i> conditions. An enhanced approach integrates dissolution and absorption measurements. However, currently-used two-compartment absorptive apparatuses, employing a flat-sheet membrane are limited, in particular by the small membrane surface area that restricts the mass transfer, resulting in unrealistic experimental timeframes. This greatly impacts the suitability of such systems as a formulation development tool. The goal of this research is two-fold. First, to develop and test a high surface area, flow-through, absorptive dissolution testing apparatus, designed to provide <i>in vivo</i> relevant information about formulation performance in biologically relevant time frames. Second, to use this apparatus to obtain mechanistic insight into physical phenomenon occurring during formulation dissolution. Herein, the design and construction of a coupled dissolution-absorption apparatus using a hollow fiber membrane module to simulate the absorption process is described. The hollow fiber membrane offers a large membrane surface area, improving the mass transfer rates significantly. Following the development of a robust apparatus, its application as a formulation development tool was evaluated in subsequent studies. The dissolution-absorption studies were carried out for supersaturated solutions generated via anti-solvent addition, pH-shift and by dissolution of amorphous formulations. The research demonstrates the potential of the apparatus to capture subtle differences between formulations, providing insight into the role of physical processes such as supersaturation, crystallization kinetics and liquid-liquid phase separation on the absorption kinetics. The study also explores dissolution-absorption performance of amorphous solid dispersions (ASDs) and the influence of resultant solution phase behavior on the absorption profile. Residual crystalline content in ASDs is a great concern from a physical stability and dissolution performance perspective as it can promote secondary nucleation or seed crystal growth. Therefore, the risk of drug crystallization during dissolution of ASDs containing some residual crystals was assessed using absorptive dissolution measurements and compared to outcomes observed using closed-compartment dissolution testing. Mesoporous silica-based formulations are another type of amorphous formulations that are gaining increased interest due to higher physical stability and rapid release of the amorphous drug. However, their application may be limited by incomplete drug release resulting from the adsorption tendency of the drug onto the silica surface. Thus, the performance of mesoporous silica-based formulations was also evaluated in the absorptive dissolution testing apparatus to determine the impact of physiological conditions such as gastrointestinal pH and simultaneous membrane absorption on the adsorption kinetics during formulation dissolution. Overall, the aim of this research was to demonstrate the potential of the novel <i>in vitro</i> methodology and highlight the significance of a dynamic absorptive dissolution environment to enable better assessment of complex enabling formulations. <i>In vivo</i>, there are multiple physical processes occurring in the gastrointestinal lumen and the kinetics of these processes strongly depend on the absorption kinetics and <i>vice-a-versa</i>. Thus, using this novel tool, the interplay between solution phase behavior and the likely impacts on bioavailability of supersaturating drug delivery systems can be better elucidated. This approach and apparatus is anticipated to be of great utility to the pharmaceutical industry to make informed decisions with respect to formulation optimization.</p>